Status:
COMPLETED
Curcumin in Patients With Mild to Moderate Alzheimer's Disease
Lead Sponsor:
John Douglas French Foundation
Collaborating Sponsors:
Institute for the Study of Aging (ISOA)
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
50+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to examine the safety and tolerability of curcumin, and to determine its effect on patients with mild to moderate Alzheimer's Disease (AD).
Detailed Description
Curcumin, a yellow substance found in the spice Turmeric, has antioxidant, non-steroidal anti-inflammatory (NSAID), and cholesterol-lowering properties, all of which make it a good candidate in the pr...
Eligibility Criteria
Inclusion
- Male or female at least 50 years old
- Diagnosis of probable AD
- No history of significant psychiatric or non-AD neurological disease
- Proficient in English to be able to perform cognitive testing
- Caregiver available to monitor and administer medication and to accompany patient to every clinical visit
- On stable doses of cholinesterase inhibitors and memantine (Alzheimer's medications) for 3 months prior to enrollment
- On stable doses of all other allowed medications for at least one month prior to starting the study medication
Exclusion
- Current or recent major psychiatric illness (i.e. bipolar disorder, schizophrenia)
- Significant, uncontrolled systemic illness (i.e. chronic renal failure, chronic liver disease, poorly controlled diabetes, or poorly controlled congestive heart failure)
- Recent history of gastrointestinal bleeding or ulceration
- Alcoholism or substance abuse within the past year
- Familial, autosomal dominant Alzheimer's disease due to a mutation in a known gene (Presenilin-1, Presenilin-2, or Amyloid Precursor Protein)
- NSAIDs (e.g. ibuprofen, naproxen, etc.) taken on a regular basis (more than 3 times per week)
- Aspirin at doses more than 325 mg per day
- Coumadin, heparin, other anticoagulants
- Antioxidants or other supplements including gingko biloba, coenzyme Q10, alpha-lipoic acid
- Vitamin E at doses more than 2,000 IU per day
- Vitamin C at doses more than 500 mg per day
Key Trial Info
Start Date :
July 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2007
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT00099710
Start Date
July 1 2003
End Date
December 1 2007
Last Update
December 3 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCLA Medical Center
Westwood, Los Angeles, California, United States